Selected discussion
Clinical evidence update from Journal of the American Veterinary Medical Association
Clinical Context
Peer-reviewed veterinary literature continues to shape everyday decision-making for canine patients, especially when new evidence clarifies diagnosis, treatment selection, monitoring, or clinical outcomes.
What the Study Evaluated
A study published in Journal of the American Veterinary Medical Association in 2026 evaluated clinical trial reveals limited clinical and microbiome effects following oral fecal microbiota transplantation in dogs with chronic enteropathy responsive to tylosin..
Key Findings
To evaluate clinical response and fecal biomarkers in dogs with tylosin-responsive enteropathy (TRE) treated with oral fecal microbiota transplantation (FMT). In this prospective, randomized, double-blind, placebo-controlled trial (conducted between August 1, 2020, and December 31, 2022), 14 client-owned dogs with confirmed tylosin-responsive enteropat…
Discussion thread
Follow the line down to read the conversation in order.
The study examines the clinical and microbiome effects of oral fecal microbiota transplantation in dogs with tylosin-responsive enteropathy. This research shares a focus on the physiological role of the gastrointestinal microbiome as a factor in overall health and internal balance. Related coverage regarding these complex biological interactions appears in Canine Gastroenterology.
Join this discussion
Add your reply
Share a professional insight, ask a focused question, or add relevant clinical experience.
Member participation
Log in to join the discussion
Share an answer, ask a question, reply to another professional, or mark useful contributions as helpful.